Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Phase 2 Terminated
17 enrolled
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Phase 1 Terminated
1 enrolled
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Phase 1 Terminated
18 enrolled
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Phase 1 Terminated
10 enrolled
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 5 charts
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Phase 1/2 Terminated
58 enrolled
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase 2 Terminated
1 enrolled 1 chart
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase 1/2 Terminated
46 enrolled 29 charts
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Terminated
12 enrolled
DMV
Phase 1/2 Terminated
13 enrolled 8 charts
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Phase 1/2 Terminated
6 enrolled 8 charts
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
11 enrolled 9 charts
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Phase 2 Terminated
4 enrolled 6 charts
TAVAB
Phase 2 Terminated
11 enrolled
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Phase 2 Terminated
2 enrolled 11 charts
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Phase 1 Terminated
20 enrolled
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
32 enrolled 12 charts
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 2 Terminated
3 enrolled 6 charts
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
7 enrolled
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Phase 2 Terminated
23 enrolled 9 charts
VRCD
Phase 2 Terminated
12 enrolled 7 charts
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 Terminated
19 enrolled 10 charts
VelRand
Phase 3 Terminated
3 enrolled 11 charts
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase 2 Terminated
27 enrolled
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase 2 Terminated
12 enrolled 10 charts
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase 2 Terminated
24 enrolled 3 charts
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
32 enrolled
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Terminated
16 enrolled 7 charts
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Phase 2 Terminated
7 enrolled 8 charts
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2 Terminated
2 enrolled 6 charts
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
Phase 3 Terminated
20 enrolled 7 charts
2007-77
Phase 3 Terminated
10 enrolled 5 charts
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
Phase 1/2 Terminated
31 enrolled 10 charts
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
Phase 2 Terminated
19 enrolled 7 charts
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Phase 2 Terminated
17 enrolled 16 charts
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Phase 2 Terminated
6 enrolled 8 charts
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Phase 1 Terminated
8 enrolled
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 6 charts
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Phase 2 Terminated
4 enrolled 7 charts
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
Phase 2/3 Terminated
23 enrolled
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Phase 2 Terminated
17 enrolled 5 charts
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Phase 2 Terminated
3 enrolled 4 charts
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Phase 1 Terminated
15 enrolled
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Phase 2 Terminated
17 enrolled 6 charts
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Phase 2 Terminated
5 enrolled 8 charts
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
6 enrolled 4 charts